Fundraising Fox
ARase Therapeutics
2 known investors
Find your way into ARase Therapeutics
Sign up to see every warm intro you have to ARase Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ARase Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Arase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways. The company focuses on developing new cancer treatments for patients with various cancer types.
Founders & leadership
PC
Paul ChangPresident, CEO / CSO and Lead FounderPaul Chang is an MIT-trained researcher who founded ARase Therapeutics and previously co-founded Ribon Therapeutics, where he served as VP of biology overseeing programs that advanced to clinical trials. He currently serves as President, CEO and Chief Scientific Officer of ARase.
WL
W. Lee KrausScientific Founder
MT
Michael TaylorExecutive ChairmanMichael Taylor is Executive Chairman of ARase Therapeutics, which develops oncology therapeutics targeting ADP-ribose Hydrolases. He has held leadership roles in drug discovery and development, business development, and corporate management.
Investors · 2
Mission Biocapital✓ confirmed by ARase TherapeuticsSan Francisco · $500K
How we know: Mission Biocapital's portfolio page · the company's own site · funding news · press coverage · the VCSheet dataset · Not right? Tell us
Related companies · 6
Atara BiotherapeuticsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Sarepta TherapeuticsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
TesseraTessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases. The company focuses on non-viral delivery methods to enable potentially curative genetic therapies.
Protara TherapeuticsProtara develops transformative therapies for patients with cancer and rare diseases, applying modern scientific and manufacturing advancements to accelerate drug development.
Samsara BiocapitalSamsara BioCapital is a venture capital firm that invests in therapeutic and biotech companies, backing scientific teams developing new drugs and medical treatments.
Companies working in the same space as ARase Therapeutics.
In the news
Frequently asked questions
- What does ARase Therapeutics do?
- Arase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways. The company focuses on developing new cancer treatments for patients with various cancer types.
- Who founded ARase Therapeutics?
- ARase Therapeutics was founded by Paul Chang, W. Lee Kraus.
- Who are ARase Therapeutics's investors?
- ARase Therapeutics's investors include Mission Biocapital, Portal Innovations.